Literature DB >> 32049506

Initial Kinetic Characterization of Sterile Alpha and Toll/Interleukin Receptor Motif-Containing Protein 1.

Heather S Loring1,2, Janneke D Icso1,2, Venkatesh V Nemmara1,2, Paul R Thompson1,2.   

Abstract

Sterile alpha and toll/interleukin receptor (TIR) motif-containing protein 1 (SARM1) plays a pivotal role in triggering the neurodegenerative processes that underlie peripheral neuropathies, traumatic brain injury, and neurodegenerative diseases. Importantly, SARM1 knockdown or knockout prevents degeneration, thereby demonstrating that SARM1 is a promising therapeutic target. Recently, SARM1 was shown to promote neurodegeneration via its ability to hydrolyze NAD+, forming nicotinamide and ADP ribose (ADPR). Herein, we describe the initial kinetic characterization of full-length SARM1, as well as the truncated constructs corresponding to the SAM1-2TIR and TIR domains, highlighting the distinct challenges that have complicated efforts to characterize this enzyme. Moreover, we show that bacterially expressed full-length SARM1 (kcat/KM = 6000 ± 2000 M-1 s-1) is at least as active as the TIR domain alone (kcat/KM = 1500 ± 300 M-1 s-1). Finally, we show that the SARM1 hydrolyzes NAD+ via an ordered uni-bi reaction in which nicotinamide is released prior to ADPR.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32049506      PMCID: PMC7085114          DOI: 10.1021/acs.biochem.9b01078

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

Review 1.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

2.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

3.  Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.

Authors:  Stefanie Geisler; Ryan A Doan; Amy Strickland; Xin Huang; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Brain       Date:  2016-10-25       Impact factor: 13.501

4.  Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels.

Authors:  E B George; J D Glass; J W Griffin
Journal:  J Neurosci       Date:  1995-10       Impact factor: 6.167

5.  SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.

Authors:  Daniel W Summers; Daniel A Gibson; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

6.  Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry.

Authors:  Anthony A Sauve; Vern L Schramm
Journal:  Biochemistry       Date:  2003-08-12       Impact factor: 3.162

7.  The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries.

Authors:  A A Sauve; C Munshi; H C Lee; V L Schramm
Journal:  Biochemistry       Date:  1998-09-22       Impact factor: 3.162

8.  Sarm1-mediated axon degeneration requires both SAM and TIR interactions.

Authors:  Josiah Gerdts; Daniel W Summers; Yo Sasaki; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2013-08-14       Impact factor: 6.167

9.  Cell body response to injury in motoneurons and primary sensory neurons of a mutant mouse, Ola (Wld), in which Wallerian degeneration is delayed.

Authors:  M A Bisby; W Tetzlaff; M C Brown
Journal:  J Comp Neurol       Date:  1995-09-04       Impact factor: 3.215

10.  dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.

Authors:  Jeannette M Osterloh; Jing Yang; Timothy M Rooney; A Nicole Fox; Robert Adalbert; Eric H Powell; Amy E Sheehan; Michelle A Avery; Rachel Hackett; Mary A Logan; Jennifer M MacDonald; Jennifer S Ziegenfuss; Stefan Milde; Ying-Ju Hou; Carl Nathan; Aihao Ding; Robert H Brown; Laura Conforti; Michael Coleman; Marc Tessier-Lavigne; Stephan Züchner; Marc R Freeman
Journal:  Science       Date:  2012-06-07       Impact factor: 47.728

View more
  7 in total

1.  Identification of the first noncompetitive SARM1 inhibitors.

Authors:  Heather S Loring; Sangram S Parelkar; Santanu Mondal; Paul R Thompson
Journal:  Bioorg Med Chem       Date:  2020-07-17       Impact factor: 3.641

2.  Pathogen infection and cholesterol deficiency activate the C. elegans p38 immune pathway through a TIR-1/SARM1 phase transition.

Authors:  Nicholas D Peterson; Janneke D Icso; J Elizabeth Salisbury; Tomás Rodríguez; Paul R Thompson; Read Pukkila-Worley
Journal:  Elife       Date:  2022-01-31       Impact factor: 8.713

Review 3.  The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease.

Authors:  Matthew D Figley; Aaron DiAntonio
Journal:  Curr Opin Neurobiol       Date:  2020-04-17       Impact factor: 6.627

4.  SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated bymultiple physiologically relevant NAD metabolites.

Authors:  Carlo Angeletti; Adolfo Amici; Jonathan Gilley; Andrea Loreto; Antonio G Trapanotto; Christina Antoniou; Elisa Merlini; Michael P Coleman; Giuseppe Orsomando
Journal:  iScience       Date:  2022-01-25

5.  STING cyclic dinucleotide sensing originated in bacteria.

Authors:  Benjamin R Morehouse; Apurva A Govande; Adi Millman; Alexander F A Keszei; Brianna Lowey; Gal Ofir; Sichen Shao; Rotem Sorek; Philip J Kranzusch
Journal:  Nature       Date:  2020-09-02       Impact factor: 49.962

Review 6.  CD38 in the age of COVID-19: a medical perspective.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Malavasi
Journal:  Physiol Rev       Date:  2021-03-31       Impact factor: 37.312

7.  A phase transition enhances the catalytic activity of SARM1, an NAD+ glycohydrolase involved in neurodegeneration.

Authors:  Heather S Loring; Victoria L Czech; Janneke D Icso; Lauren O'Connor; Sangram S Parelkar; Alexandra B Byrne; Paul R Thompson
Journal:  Elife       Date:  2021-06-29       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.